CBIO · NASDAQ
Crescent Biopharma (CBIO) Stock Price & Fundamentals
Crescent Biopharma (CBIO) closed at $607.44 on Oct 9, 2026, up 0.13% from the previous close of $606.63.
Share price, past year
1Y +18.81%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $607.44 |
| Sep 30, 2026 | $599.53 |
| Aug 31, 2026 | $643.65 |
| Jul 31, 2026 | $603.07 |
| Jun 30, 2026 | $581.81 |
| May 29, 2026 | $573.08 |
| Apr 30, 2026 | $558.65 |
| Mar 31, 2026 | $511.04 |
| Feb 27, 2026 | $488.59 |
| Jan 30, 2026 | $479.37 |
| Dec 31, 2025 | $492.36 |
| Nov 28, 2025 | $468.24 |
| Oct 31, 2025 | $490.05 |
Key statistics
- Market cap
- $16.86B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- −$96.03M
- Shares outstanding
- 27.8M
- Dividend yield
- —
- 52-week range
- $457.89 – $650.24
Crescent Biopharma's market cap is $16.86B, based on a share price of $607.44 and 27.8M shares outstanding as of Jun 30, 2026.
Financials
Crescent Biopharma reported revenue of $10.84M for fiscal 2025.
Crescent Biopharma reported a net loss of $153.94M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $10.84M | +108,340.0% | −$153.94M | −1,419.6% | — | −$72.45M |
| FY2023ended Dec 31, 2023 | $10.00K | −86.7% | −$36.90M | −368,994.2% | −$0.58 | −$34.90M |
| FY2022ended Dec 31, 2022 | $75.00K | −93.5% | −$46.69M | −62,251.7% | −$0.89 | −$46.54M |
| FY2021ended Dec 31, 2021 | $1.16M | −88.6% | −$63.43M | −5,469.0% | −$1.23 | −$57.50M |
| FY2020ended Dec 31, 2020 | $10.16M | +54,834.8% | −$51.03M | −502.1% | −$1.12 | −$39.31M |
| FY2016ended Dec 31, 2016 | $18.50K | −99.9% | −$31.81M | −171,945.1% | −$1.50 | −$30.44M |
| FY2015ended Dec 31, 2015 | $20.07M | +33.6% | — | — | −$0.67 | — |
| FY2014ended Dec 31, 2014 | $15.03M | +276.4% | — | — | — | — |
| FY2013ended Dec 31, 2013 | $3.99M | −73.8% | — | — | — | — |
| FY2012ended Dec 31, 2012 | $15.26M | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$24.84M | — |
| Q1 FY2026ended Mar 31, 2026 | $1.04M | −$23.28M | — |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$21.79M | — |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$15.15M | — |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$17.87M | −$0.24 |
| Q2 FY2022ended Jun 30, 2022 | $75.00K | — | — |
| Q4 FY2021ended Dec 31, 2021 | $17.62K | — | — |
| Q3 FY2021ended Sep 30, 2021 | $86.56K | — | — |
Company profile
- Name
- Crescent Biopharma, Inc.
- Ticker
- CBIO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 300 Fifth Avenue, Waltham, MA 02451
- Incorporated in
- E9
- Fiscal year ends
- December
- SEC CIK
- 0001253689
Recent SEC filings
- Jul 30, 2026
- Jul 30, 2026
- Jul 15, 2026
- Jul 14, 2026
- Jun 22, 2026
- Jun 3, 2026
- Apr 29, 2026
- Apr 29, 2026
Frequently asked questions
What is Crescent Biopharma's stock price?
Crescent Biopharma (CBIO) closed at $607.44 on Oct 9, 2026, up 0.13% from the previous close of $606.63.
What is Crescent Biopharma's market cap?
Crescent Biopharma's market cap is $16.86B, based on a share price of $607.44 and 27.8M shares outstanding as of Jun 30, 2026.
How much revenue does Crescent Biopharma make?
Crescent Biopharma reported revenue of $10.84M for fiscal 2025.
Does Crescent Biopharma pay a dividend?
Crescent Biopharma's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Crescent Biopharma, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures